Trial Profile
A Study to Evaluate the Efficacy and Safety of Everolimus Containing Immunosuppressive Therapy in Renal Transplant Recipients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 24 Dec 2015 New trial record